Patients recruited: 970 of 1150

The EORTC 26052 trial is investigating whether intensification of temozolomide chemotherapy after combined radiochemotherapy with temozolomide improves survival in patients with glioblastoma. This study, which is recruiting very rapidly, particularly in the United States, is being conducted at only a few German centers. This study prospectively investigates the relevance of MGMT.